cardiac failure

Highlights TCT 2019

TCT 2019 | COAPT Cost Effectiveness: Better Quality of Life and Survival Rate, but Worth It?

Courtesy of SBHCI. The COAPT showed transcatheter repair of the mitral valve using the MitraClip resulted in reduced mortality and hospitalization for cardiac failure and improved quality of life, compared against optimal medical treatment in patients with cardiac failure and moderate to severe functional mitral regurgitation. The cost-effectiveness of this procedure has not been analyzed<a href="https://solaci.org/en/2019/10/01/tct-2019-coapt-cost-effectiveness-better-quality-of-life-and-survival-rate-but-worth-it/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | COAPT at 3 Years: MitraClip Reached Functional Mitral Regurgitation Target

Courtesy of SBHCI. Prognosis of patients with cardiac failure who develop secondary mitral regurgitation due to dilation is uncertain.&nbsp;&nbsp; The COAPT study was carried out in 78 centers across the US and Canada and included patients with moderate to severe mitral regurgitation (3 or 4 crossovers) symptomatic despite optimal medical treatment (OMT).&nbsp; 614 patients were<a href="https://solaci.org/en/2019/10/01/tct-2019-coapt-at-3-years-mitraclip-reached-functional-mitral-regurgitation-target/" title="Read more" >...</a>

ESC 2019 | MITRA-FR: los resultados a 2 años de uno de los grandes estudios del MitraClip

ESC 2019 | MITRA-FR: 2-Year Outcomes of One of the Largest Studies on MitraClip

Negative one-year outcomes of Mitra-FR led to several discussions and hypothesis, especially after the COAPT was published only a few weeks later. According to the COAPT study, the MitraClip was able to reduce hospitalization rate for cardiac failure and also all-cause mortality, compared against optimal medical treatment alone. When comparing the COAPT to the Mitra-FR,<a href="https://solaci.org/en/2019/09/06/esc-2019-mitra-fr-2-year-outcomes-of-one-of-the-largest-studies-on-mitraclip/" title="Read more" >...</a>

ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.

The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in patients with cardiac failure symptoms and preserved ejection fraction, according to the new study presented on Sunday at ESC 2019 scientific session in Paris and simultaneously published in NEJM. Despite the negative results, we remain hopeful that this<a href="https://solaci.org/en/2019/09/03/esc-2019-paragon-hf-sacubitril-valsartan-somewhat-disappointing-though-a-few-would-benefit/" title="Read more" >...</a>

B Blockers

Must Post MI Patients Use B Blockers for Life?

Long-term use of B blockers after myocardial infarction has been questioned for a while now; in fact, admittedly, beyond the three year follow up its benefits remain unclear. It is particularly controversial in elderly patients and this recent study published in Circ Cardiovasc Qual Outcomes sheds some light on the matter. The study followed 6893<a href="https://solaci.org/en/2019/08/22/must-post-mi-patients-use-b-blockers-for-life/" title="Read more" >...</a>

Sinus Aspiration against Contrast Induced Kidney Injury

Mechanisms of Post PCI Persistent Angina

Angina persistence or recurrence after PCI can affect between 20 to 40% of patients in the short and mid-term. This might be true despite PCI optimization using FFR, intravascular ultrasound and the latest generation stents. This problem is associated with high healthcare cost, which can double in patients with recurrent or persistent angina compared against<a href="https://solaci.org/en/2019/08/22/mechanisms-of-post-pci-persistent-angina/" title="Read more" >...</a>

Post TAVR New Onset Left Bundle Branch Block at Long Term: Worth Our Attention?

After post TAVR mean 3-year follow-up, a new onset persistent left bundle branch block (LBBB) was not associated with higher mortality or hospitalization for cardiac failure according to this study to be published soon in J Am Coll Cardiol Intv. Nevertheless, LBBB was associated to higher risk of definite pacemaker and a negative impact in<a href="https://solaci.org/en/2019/06/05/post-tavr-new-onset-left-bundle-branch-block-at-long-term-worth-our-attention/" title="Read more" >...</a>

EuroPCR 2019 | TRILUMINATE: Reparación tricuspídea con clip mejora la insuficiencia y la calidad de vida

EuroPCR 2019 | TRILUMINATE: Tricuspid Repair with Clip Improves Regurgitation and Quality of Life

Transcatheter therapy offers a promise for a largely forgotten valve given the lack of therapeutic options. Percutaneous edge-to-edge repair with clip seems to offer some hope to patients with tricuspid regurgitation according to the TRILUMINATE. At 30 days, transcatheter repair with clip significantly reduced tricuspid regurgitation at least in one grade in most patients, which<a href="https://solaci.org/en/2019/05/24/europcr-2019-triluminate-tricuspid-repair-with-clip-improves-regurgitation-and-quality-of-life/" title="Read more" >...</a>

EuroPCR 2019 | COAPT: la reducción de la insuficiencia mitral está asociada a menos hospitalizaciones y muerte

EuroPCR 2019 | COAPT: Mitral Valve Reduction is Associated to Lower Hospitalization and Death

This new analysis shows the mechanism behind the benefit of using MitraClip and the necessary degree of residual mitral regurgitation (MR) to have an impact. Regardless the intervention type, patients with cardiac failure and secondary mitral regurgitation present lower hospitalization for cardiac failure, all-cause mortality and improved quality of life the lower the MR. MitraClip<a href="https://solaci.org/en/2019/05/23/europcr-2019-coapt-mitral-valve-reduction-is-associated-to-lower-hospitalization-and-death/" title="Read more" >...</a>

MitraClip in the “Real World”

Courtesy of Dr. Carlos Fava. Mitral regurgitation (MR) is the most frequent valvulopathy in Europe and US, affecting close to 10% of patients over 75, with more morbidity and mortality. The treatment of choice is percutaneous repair instead of replacement, to maintain the sub-valvular apparatus that contributes to systole. This is feasible and has better<a href="https://solaci.org/en/2019/05/10/mitraclip-in-the-real-world/" title="Read more" >...</a>

Top